Communiqués Armata Pharmaceuticals, Inc.

Actions

ARMP

US04216R1023

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 18/09/2026			Varia. 5j.	Varia. 1 janv.
4,180 ^USD	+1,95%		-22,30%	-33,44%

14/09	Armata Pharmaceuticals : la FDA accorde le statut de 'Breakthrough Therapy' à l'AP-SA02	MT
14/09	Armata Pharmaceuticals reçoit la désignation de 'Breakthrough Therapy' de la FDA pour l'AP-SA02	CI

Communiqués

14/09	Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02	PR
10/09	Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	PR
03/09	Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials	PR
12/08	Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update	PR
20/07	Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02	PR
13/07	Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia	PR
23/06	Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02	PR
13/05	Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update	PR
07/05	Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02	PR
04/05	Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"	PR
27/04	Armata Pharmaceuticals : 2026 Annual Meeting Proxy	PU
27/04	Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors	PR
25/03	Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results	PR
23/02	Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02	PR
14/01	Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated Staphylococcus aureus Bacteremia	AQ
13/01	/C O R R E C T I O N -- Armata Pharmaceuticals, Inc./	PR
18/11	Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST	PR
12/11	Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update	PR
10/11	Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California	PR
28/10/25	Could the Next Breakthrough in Antibiotic Resistance Come From Viruses That Kill Bacteria?	AQ
22/10/25	Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™	PR
14/10/25	Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™	PR
08/09/25	Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology	PR
04/09/25	Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference	PR
12/08/25	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update	PR